After reportedly flirting with going public for years, the artificial intelligence-powered drug developer Insilico Medicine has laid out plans to raise about $292 million through a listin | The IPO ...

Chai Discovery, an artificial intelligence drug-discovery company backed by Sam Altman’s OpenAI, has secured $130 million ...

After a year of progress, scientists say they are on the cusp of turning AI-designed antibodies into potential therapies. In ...

The two investment firms were joined by more than a half dozen other backers. The consortium included OpenAI Group PBC and ...

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

Galux signed a research agreement with Boehringer Ingelheim to advance AI-driven precision protein design for next-generation ...

In a university lab, an AI system generated millions of novel molecules to fight drug-resistant infections. And they’re working. Inside a lab at the Massachusetts Institute of Technology late last ...

Traditionally, developing a new drug takes many years and requires a massive financial investment, often involving significant risk and a high likelihood of failure. AI models trained on extensive ...

Integrating computational models (SELFormer, AlphaFold2, scConGraph, PROTAC-RL) with multi-omics data to validate historically undruggable targets (e.g., KRAS via ...